Cosmo Pharmaceuticals N.V
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more
Market Cap & Net Worth: Cosmo Pharmaceuticals N.V (CMOPF)
Cosmo Pharmaceuticals N.V (PINK:CMOPF) has a market capitalization of $1.06 Billion ($1.06 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #9975 globally and #4689 in its home market, demonstrating a 0.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cosmo Pharmaceuticals N.V's stock price $62.80 by its total outstanding shares 16876011 (16.88 Million).
Cosmo Pharmaceuticals N.V Market Cap History: 2017 to 2025
Cosmo Pharmaceuticals N.V's market capitalization history from 2017 to 2025. Data shows growth from $2.28 Billion to $1.06 Billion (0.00% CAGR).
Cosmo Pharmaceuticals N.V Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cosmo Pharmaceuticals N.V's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.40x
Cosmo Pharmaceuticals N.V's market cap is 4.40 times its annual revenue
0.84x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
8.82x
Cosmo Pharmaceuticals N.V's market cap is 8.82 times its annual earnings
11.15x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.28 Billion | $67.24 Million | -$32.45 Million | 33.97x | N/A |
| 2018 | $1.59 Billion | $65.62 Million | -$18.06 Million | 24.28x | N/A |
| 2019 | $1.31 Billion | $62.49 Million | -$24.49 Million | 20.99x | N/A |
| 2020 | $1.38 Billion | $60.95 Million | -$7.90 Million | 22.62x | N/A |
| 2021 | $1.12 Billion | $65.07 Million | $21.67 Million | 17.21x | 51.68x |
| 2022 | $1.08 Billion | $102.09 Million | $17.23 Million | 10.60x | 62.83x |
| 2023 | $842.89 Million | $92.78 Million | -$4.93 Million | 9.08x | N/A |
| 2024 | $1.17 Billion | $266.79 Million | $133.24 Million | 4.40x | 8.82x |
Competitor Companies of CMOPF by Market Capitalization
Companies near Cosmo Pharmaceuticals N.V in the global market cap rankings as of March 18, 2026.
Key companies related to Cosmo Pharmaceuticals N.V by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Cosmo Pharmaceuticals N.V Historical Marketcap From 2017 to 2025
Between 2017 and today, Cosmo Pharmaceuticals N.V's market cap moved from $2.28 Billion to $ 1.06 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $1.06 Billion | -9.80% |
| 2024 | $1.17 Billion | +39.39% |
| 2023 | $842.89 Million | -22.12% |
| 2022 | $1.08 Billion | -3.37% |
| 2021 | $1.12 Billion | -18.78% |
| 2020 | $1.38 Billion | +5.13% |
| 2019 | $1.31 Billion | -17.66% |
| 2018 | $1.59 Billion | -30.27% |
| 2017 | $2.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Cosmo Pharmaceuticals N.V was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.06 Billion USD |
| MoneyControl | $1.06 Billion USD |
| MarketWatch | $1.06 Billion USD |
| marketcap.company | $1.06 Billion USD |
| Reuters | $1.06 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.